Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2 Acorda Therapeutics.

today announced the National Heart, Lung, and Blood Institute provides awarded a $1 million Cardiac Translational Research Implementation System grant to aid research on Glial Development Factor 2 , a novel investigational agent for the treating patients with heart failure under advancement at Acorda. The grant, supporting both medical and laboratory studies, was awarded to Acorda and Vanderbilt University Heart and Vascular Institute jointly, which are collaborating on analysis of GGF2 in center failure. The first clinical research for GGF2 in individuals with heart failure is expected to begin in mid-2010.D., Ph.D., Vice President of Preclinical Advancement at Acorda.Samani, F.R.C.P. For the CARDIoGRAM+C4D Consortium: Genetically Determined Elevation and Coronary Artery Disease There is a well-established association between a shorter adult height and an elevated threat of coronary artery disease .1 Shorter stature is also connected with risk factors for CAD, including high blood circulation pressure, high levels of low-density lipoprotein cholesterol, and diabetes.2,3 An individual-level meta-analysis showed a loss of 1 SD in height was associated with a relative increase of 8 percent in the risk of fatal or non-fatal CAD.2 The result was largely unchanged after adjustment for smoking status, systolic blood pressure, background of diabetes, body-mass index, lipid markers, alcohol consumption, education level, and occupation.2 Therefore, the precise mechanisms linking shorter height with an elevated risk of CAD remain unclear.